October 21, 2016
The Roadblock for Generic Drugs: Declaratory Judgment Jurisdiction for Later Generic Challengers
The Hatch-Waxman Act allows generic drug manufacturers to market a generic equivalent of a pharmaceutical company’s patented drug prior to the patent’s expiration by bringing Paragraph IV challenges against the patent holder. To encourage generic manufacturers to make these challenges, the Hatch-Waxman Act grants the first generic challenger (“first-filer”) for a particular drug a 180-day period of marketing exclusivity during which the Food and Drug Administration (“FDA”) will not approve applications from later generic challengers (“later-filers”). However, the first-filer almost always enters into reverse-payment settlement agreements with the pharmaceutical patent holder, where the patent holder agrees to pay the generic challenger to postpone entering the market. These settlement agreements act as roadblocks for later-filers.
One of the only ways for a later-filer to overcome such a roadblock is to bring a declaratory judgment action against the pharmaceutical patent holder. Early decisions by the Federal Circuit, however, suggested that later-filers could not bring declaratory judgment actions because they failed to satisfy the Constitution’s Article III “case or controversy” requirement.
Matthew Avery & Mary Nguyen, The Roadblock for Generic Drugs: Declaratory Judgment Jurisdiction for Later Generic Challengers, 15 N.C. J.L. & Tech. 1 (2013), available at http://ncjolt.org/wp-content/uploads/2013/11/Avery-+-Nguyen-Final.pdf.
The North Carolina Journal of Law & Technology has adopted the Open Access Program, a part of the Scholar’s Copyright Project created by Science Commons. Authors designate the conditions under which their articles are licensed. By downloading articles, you agree to comply with the license terms specified. Click here to see a copy of our Publication Agreement. Please contact NC JOLT at email@example.com with permissions inquiries.